Nabi Pharmaceuticals, Hedge Fund Reach Deal on Directors, Chairman
15th Nov 2006, 02:36 GMT
By Stephen Pounds, The Palm Beach Post, Fla. Nov. 14--Nabi Biopharmaceuticals Inc. and New York-based hedge fund Third Point LLC announced Monday they have reached a settlement on Third Point's plans to unseat Chairman Tom McLain and a majority of Nabi's board.
Nabi Pharmaceuticals, Hedge Fund Reach Deal on Directors, Chairman related news:
- Nabi, Third Point agree to board changes — Latest news from South Florida Business Journal
- Nabi, 3rd Point agree to board changes — Financial News News from StratCenter.com
- Large hits at London's hedge fund listing ban — TimesOnline: Business
- Business and philanthropy in a sometimes rocky union — Europe - International Herald Tribune
- Investcorp partners US hedge fund — AME Info News - Finance and Economy
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement — Bio-Technology News from StratCenter.com
- Marshall Wace plans £1bn fund — Telegraph Business
- Marshall Wace Plans Hedge-Fund IPO — WSJ.com: What's News Europe
- Fortis Investments acquires majority stake in fund of hedge funds firm — Banking Business Review Latest News
- Marshall Wace aims for €1.5bn listing — FT.com - UK Homepage
Latest news from RedOrbit News - Health:
- Pet Shop Boys Fans Know Better _ Why Bother Sharing?
- Corcept Tests Psych. Major Depression Rx
- On Its 30th Anniversary, Smokeout Provides Even More Help Quitting Smoking
- Health Plans and Disease Management Companies Are Seeking To Reduce the Use of the ER for Non-Urgent Care - Urgent Emergency Room Usage October 18, 2006 Audio Conference on CD-ROM
- Invitation Conference Call Analyst Meeting
- As Benefit Costs Rise, Employee Retirement Savings Decline
- Aetna to Help Members Quit Tobacco With New Tobacco Cessation Program
- Lilly: Arxxant Cuts Sight Loss in Diabetes
- SW Doctors PA Launch Affordable Primary Care (APC) Services
- Health Savings Technology Appoints New Management Team to Spearhead Growth in Customer-Directed Healthcare Industry